Outcomes by transarterial chemoembolization (TACE) modality from participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D)+bevacizumab (B)+TACE and placebos (PBO)+TACE: EMERALD-1 subgroup analysis

Puntos clave

• Improved progression-free survival was observed in patients treated with durvalumab plus TACE compared to placebo plus TACE.
• The analysis reported a hazard ratio of 0.77, suggesting a significant survival benefit in the combination treatment group.
• Types of TACE, including conventional TACE and drug-eluting bead TACE, were evaluated for their impact on treatment outcomes.
• Further exploration of TACE modality effects may support personalized treatment strategies in hepatocellular carcinoma.